Feedback / Questions
dilanubicel (DVX101) - Deverra Therapeutics
https://www.accesswire.com/856279/deverra-therapeutics-granted-fda-fast-track-designation-for-dvx101-dilanubicel-for-the-treatment-of-acute-myeloid-leukemia
Apr 24, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next